This multi-center, multi-vendor study will validate a rapid magnetic resonance-based confounder- corrected R2* mapping method as a quantitative imaging biomarker of liver iron concentration (LIC). Excessive accumulation of iron in various organs, including the liver, which affects both adult and pediatric populations, is toxic and requires treatment aimed at reducing body iron stores. Measurement of LIC is critical for detection and staging of iron overload, and for monitoring iron-reducing chelator therapies that are expensive and have side effects. Magnetic Resonance Imaging (MRI) is a widely available, accessible, and safe technology, and it is very sensitive to the presence of iron in tissue. Translation of an MRI biomarker of liver iron concentration into broad clinical use requires that i is clinically feasible, precise, robust to changes in scan parameters, calibrated to a validated reference standard of LIC, and is reproducible across sites and manufacturers. There are currently no available MRI methods that meet these requirements. R2*-MRI holds the greatest promise to meet these requirements. R2* mapping can be performed very rapidly with whole-liver 3D coverage in a single 20s breath-hold. Past work has demonstrated excellent correlation and linear calibration between R2* and LIC. However, current R2*-MRI methods are affected by three key confounding factors: [1] fat, [2] noise, and [3] magnetic field variations. A quantitativ confounder- corrected R2*-MRI method developed at the University of Wisconsin shows great promise to address the shortcomings of current R2*-MRI methods. By addressing the confounding effects of fat, noise, and magnetic field variations, this single breath-hold method is robust to changes in protocol and is precise (repeatable) with multiple measurements. Preliminary clinical data of the confounder-corrected R2* method demonstrates linear calibration with LIC with excellent correlation. Preliminary phantom studies show excellent reproducibility across sites and MRI manufacturers. However, the performance and reproducibility of this technique for in vivo liver iron quantification across different sites and platforms have yet to be validated. Therefore, the goal of this proposal is to validate rapid confounder-corrected R2*-MRI as a biomarker for liver iron overload in a multi-center study (participating sites: Stanford, UT-Southwestern, Johns Hopkins and UW-Madison), including the three main MRI vendors (GE, Siemens and Philips) at different field strengths (1.5T and 3T), in adults and pediatrics with live iron overload. Specifically, we aim to establish the [1] precision and [2] robustness of confounder-corrected R2*-MRI, [3] to calibrate R2* MRI to LIC at 1.5T and 3.0T, and [4] to establish the reproducibility of R2* across manufacturer and site. Successful validation of confounder-corrected R2*-MRI is needed to translate this method into a biomarker that is independent of site, platform, and scan parameters, and would provide a universal and standardized method to assess body iron content with widespread impact and clinical applicability.

Public Health Relevance

The overall goal of this research is to validate a new, rapid, and non-invasive method to measure iron concentration in the liver with magnetic resonance imaging (MRI). Toxic levels of iron can accumulate in the liver due to many conditions such as certain hereditary diseases and in patients who receive a large number of blood transfusions. We will test the performance of the new method in patients at four different institutions, in order to translate it into widespread clinical practice and provide physicians with a validated method for diagnosis and treatment monitoring of iron overload.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Bishop, Terry Rogers
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
Schools of Medicine
United States
Zip Code
Colgan, Timothy J; Hernando, Diego; Sharma, Samir D et al. (2016) The effects of concomitant gradients on chemical shift encoded MRI. Magn Reson Med :
Kinner, Sonja; Reeder, Scott B; Yokoo, Takeshi (2016) Quantitative Imaging Biomarkers of NAFLD. Dig Dis Sci 61:1337-47
Kasza, Ildiko; Hernando, Diego; Roldán-Alzate, Alejandro et al. (2016) Thermogenic profiling using magnetic resonance imaging of dermal and other adipose tissues. JCI Insight 1:e87146
Wang, Xiaoke; Hernando, Diego; Reeder, Scott B (2016) Sensitivity of chemical shift-encoded fat quantification to calibration of fat MR spectrum. Magn Reson Med 75:845-51
Vasanawala, Shreyas S; Nguyen, Kim-Lien; Hope, Michael D et al. (2016) Safety and technique of ferumoxytol administration for MRI. Magn Reson Med 75:2107-11
Mahlke, Christoph; Hernando, Diego; Jahn, Christina et al. (2016) Quantification of liver proton-density fat fraction in 7.1T preclinical MR systems: Impact of the fitting technique. J Magn Reson Imaging :
Hernando, Diego; Sharma, Samir D; Aliyari Ghasabeh, Mounes et al. (2016) Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. Magn Reson Med :
Sharma, Samir D; Fischer, Roland; Schoennagel, Bjoern P et al. (2016) MRI-based quantitative susceptibility mapping (QSM) and R2* mapping of liver iron overload: Comparison with SQUID-based biomagnetic liver susceptometry. Magn Reson Med :
Rehm, Jennifer L; Wolfgram, Peter M; Hernando, Diego et al. (2015) Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women. Eur Radiol 25:2921-30
Kühn, Jens-Peter; Berthold, Friederike; Mayerle, Julia et al. (2015) Pancreatic Steatosis Demonstrated at MR Imaging in the General Population: Clinical Relevance. Radiology 276:129-36

Showing the most recent 10 out of 20 publications